hotspot -WSS

hotspot

author：leisure time 2025-09-30 23:40:56 - browse：21641

JOSEPH PREZIOSO/AFP via Getty Images

LONDON — The U.K.’s cost-effectiveness watchdog said Thursday it is not yet recommending Vertex’s CRISPR-based therapy for sickle cell disease, saying in draft guidance it has questions about the medicine’s lasting benefits for patients.

U.K. regulators approved the therapy, known as Casgevy or exa-cel, last year, granting it the world’s first authorization for any CRISPR-based medicine. But observers have been watching to see how the U.K.’s National Institute for Health and Care Excellence, as well as similar agencies in European countries, would view the pricey, one-time therapy. NICE needs to recommend the therapy for it to be offered in the National Health Service.

In the U.S., Casgevy has a list price of $2.2 million. It was developed by Vertex in partnership with CRISPR Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Timeline: Key moments in fight for gay rights

Wikipedia

WSS

Timeline: Key moments in fight for gay rights

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

Patients, doctors are clashing about side effects of hormonal birth control

Inside the rise of 'mukbang' eating videos

Millions may soon lose Medicaid when they don't have to

A public health expert passes on football's full body collisions for youths

Wikipedia

hotspot

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

The thinking behind the controversial eating disorder chatbot Tessa

Duchenne breakthrough therapy leaves behind pioneering families

A public health expert passes on football's full body collisions for youths

Guidelines to prevent youth baseball injuries need more muscle

The thinking behind the controversial eating disorder chatbot Tessa

DIEP, the 'gold standard' of breast reconstruction, is under threat

Eli Lilly’s Mounjaro succeeds in second weight

entertainment

Inside the rise of 'mukbang' eating videos

Millions may soon lose Medicaid when they don't have to

Senate panel passes drug pricing bills, but drops one PBM reform

Eli Lilly’s Mounjaro succeeds in second weight

Novo: Oral version of Ozempic leads to 15% weight loss

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

focus

Wikipedia

hotspot

hotspot